SOX9 is overexpressed in both colorectal cancer [40] and hormone-refractory prostate cancer [41] and has been correlated with poor patient survival in colorectal cancer [40] and enhanced in vivo tumor growth, angiogenesis, and invasion in a LNCaP prostate cancer xenograft model [42]. Here, SOX9 is linked to colorectal cancer.